Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)
复制标题
DOI：
10.1210/jc.85.11.4099
复制
发表时间：
2000-11-01
影响因子：
5.8
通讯作者：
Tamburrano, G
中科院分区：
文献类型：
--
作者：
Baldelli, R;Colao, A;Tamburrano, G
近年来，随着新的长效生长抑素类似物的出现，肢端肥大症的药物治疗得到了改善;它们被建议作为垂体手术和放疗的替代治疗。为了避免长期治疗期间每日多次注射的不便，在治疗管理中引入了兰瑞肽（LAN）的缓释制剂，以每7 - 14天30 mg的剂量肌肉注射给药。短期LAN治疗对GH和胰岛素样生长因子I（IGF-I）高分泌的抑制作用与SC奥曲肽相似。然而，很少有关于这种药物长期治疗的数据报告。在本研究中，在118例活动性肢端肥大症患者中评价了24个月LAN治疗的疗效和耐受性; 71例既往接受过手术并接受过SC奥曲肽治疗（手术患者），24例既往接受过手术并接受过SC奥曲肽治疗（放疗患者），其余23例为新诊断患者（初治患者）。根据控制的GH（空腹，
Pharmacotherapy of acromegaly has been improved in recent years as new long-acting somatostatin analogs have became available; they have been suggested as an alternative treatment to pituitary surgery and radiotherapy. To avoid the inconvenience of multiple daily injections during long-term therapy, a slow release formulation of lanreotide (LAN), to be administered im at a dose of 30 mg every 7-14 days, has been introduced in the therapeutic management. The suppressive effects of a short-term LAN treatment on GH and insulin-like growth factor I (IGF-I) hypersecretion were shown to be similar to those obtained with sc octreotide. However, scant data have been reported concerning a long-term treatment with this drug. In the present study the efficacy and tolerability of a 24-month LAN treatment were evaluated in 118 active acromegalic patients; 71 had been previously operated on and treated with sc octreotide (operated patients), 24 previously operated on had been irradiated and treated with sc octreotide (irradiated patients), and the remaining 23 were newly diagnosed (de novo patients). The efficacy was considered on the basis of controlled GH (fasting,